Clinical predictors of methicillin-resistance and their impact on mortality associated with Staphylococcus aureus bacteraemia

Epidemiology and Infection
Yu Mi WiKyong Ran Peck

Abstract

We investigated the clinical predictors of methicillin-resistance and their impact on mortality in 371 patients with Staphylococcus aureus bacteraemia identified from two prospective multi-centre studies. Methicillin resistant S. aureus (MRSA) accounted for 42.2% of community-onset and 74.5% of hospital-onset cases. No significant clinical difference was found between patients infected with MRSA vs. methicillin-sensitive S. aureus (MSSA), except that the former were more likely to have had hospital-onset bacteraemia and received antibiotics in the preceding 90 days. After stratifying according to the acquisition site, prior antibiotic use was the only independent predictor of having MRSA in both community-onset and hospital-onset cases. The frequency of inappropriate empirical antibiotic therapy was higher in patients with MRSA than in those with MSSA bacteraemia. However, methicillin resistance was not a predictor of mortality in patients and the clinical characteristics and outcomes of both MRSA and MSSA bacteraemia were similar. This study indicates that there are no definitive clinical or epidemiological risk factors which could distinguish MRSA from MSSA cases with the exception of the previous use of antibiotics for havin...Continue Reading

References

May 4, 1989·The New England Journal of Medicine·W Brumfitt, J Hamilton-Miller
Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J S LiG R Corey
Nov 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J M Mylotte, A Tayara
Dec 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveYehuda Carmeli
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseMichael J Rybak
Apr 9, 2004·Critical Care Medicine·Kevin B LauplandDeirdre L Church
Jun 19, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L PatersonVictor L Yu
Mar 11, 2005·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Sara E CosgroveYehuda Carmeli
Mar 11, 2005·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Shelby D ReedVance G Fowler
Apr 9, 2005·The New England Journal of Medicine·Scott K FridkinUNKNOWN Active Bacterial Core Surveillance Program of the Emerging Infections Program Network
May 24, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sheldon L KaplanEdward O Mason
Jun 21, 2005·Diagnostic Microbiology and Infectious Disease·Thomas P Lodise, Peggy S McKinnon
Mar 1, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R KhatibL B Johnson
Jan 24, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Loren G MillerBrad Spellberg
Apr 25, 2007·Archives of Internal Medicine·Daniel Z UslanLarry M Baddour
Nov 7, 2007·Antimicrobial Agents and Chemotherapy·Sung-Han KimKang-Won Choe
Sep 30, 2008·Scandinavian Journal of Infectious Diseases·Riad KhatibK Riederer
Sep 3, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D MarchaimY Carmeli
Nov 26, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Natalie L McCarthyDavid Rimland
May 8, 2010·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Dolunay GülmezGülşen Hasçelik
Oct 16, 2010·The Journal of Antimicrobial Chemotherapy·Mical PaulLeonard Leibovici
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Jae-Hoon SongUNKNOWN ANSORP Study Group
Dec 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Clare E MillerJonathan D Edgeworth
Apr 12, 2012·Clinical Microbiology Reviews·Sebastian J van HalIain B Gosbell
Jan 22, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·O GaschUNKNOWN REIPI/GEIH Study Groups
Jan 23, 2013·Revista Panamericana De Salud Pública = Pan American Journal of Public Health·Juan S CastilloUNKNOWN GREBO
Feb 2, 2013·International Journal of Medical Microbiology : IJMM·J Natalia JiménezMargarita M Correa
Feb 14, 2013·The Journal of Antimicrobial Chemotherapy·O GaschUNKNOWN REIPI/GEIH Study Groups
Nov 26, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James D ChalmersSantiago Ewig
Jul 18, 2014·Journal of Clinical Microbiology·Natasha E HolmesBenjamin P Howden
Feb 11, 2016·Annals of Clinical Microbiology and Antimicrobials·Mesut YilmazAli Mert
Oct 23, 2016·The Lancet Infectious Diseases·Stefano AlibertiUNKNOWN GLIMP investigators
Dec 20, 2016·Biomédica : revista del Instituto Nacional de Salud·Paola Mariana Arias-OrtizGrupo Grebo
May 6, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sun Young Cho, Doo Ryeon Chung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.